Table 2 Frequency distribution of changes in best-corrected visual acuity from baseline to month 6
| Change in BCVA | Eyes, n (%) | |
| Bevacizumab (n = 14) | PDT plus IVTA (n = 14) | |
| ⩾3-Line increase | 5 (36) | 3 (21) |
| 0 to <3-Line increase | 7 (50) | 4 (29) |
| <3-Line decrease | 2 (14) | 5 (36) |
| ⩾3-Line decrease | 0 (0) | 2 (14) |
-
BCVA, Best-corrected visual acuity; IVTA, intravitreal triamcinolone; PDT, verteporfin therapy.
